Sg3 Management, LLC Rigel Pharmaceuticals Inc Transaction History

Sg3 Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$2.36 - $3.57 $217,016 - $328,282	-91,956 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.5 - $4.5 $181,846 - $233,802	51,956 Added 129.89%	91,956 $334,000
Q2 2021 Aug 16, 2021	SELL	$3.09 - $4.54 $71,997 - $105,782	-23,300 Reduced 36.81%	40,000 $174,000
Q1 2021 May 17, 2021	BUY	$3.35 - $4.93 $19,430 - $28,594	5,800 Added 10.09%	63,300 $216,000
Q4 2020 Feb 16, 2021	BUY	$2.35 - $3.74 $135,125 - $215,050	57,500 New	57,500 $201,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $4.82B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.